908 Devices has acquired NIRLAB, a Swiss-based company and a spin-off from the University of Lausanne, for an undisclosed amount. NIRLAB develops an innovative digital ecosystem that enables the on-site analysis, identification, and quantification of substances and materials within seconds. This is achieved with lab-grade accuracy using Near-Infrared (NIR) Spectroscopy combined with advanced machine learning algorithms.
NIRLAB's mobile AI lab solutions have a broad range of applications, including the identification and quantification of over 150 narcotics such as heroin, cocaine, THC/CBD levels, and MDMA. Their technology also supports the identification of polymers for plastic sorting and recycling, quantification of fat levels and pigments in living salmon, measurement of sucrose levels in sugar cane, and the identification of counterfeit medicines like Viagra. The company currently provides high-precision field labs to businesses in over 35 countries.
This strategic acquisition is expected to significantly enhance 908 Devices' capabilities in delivering advanced, real-time analytical solutions. By integrating NIRLAB's innovative NIR Spectroscopy and machine learning platform, 908 Devices aims to expand its portfolio of on-site analysis tools, offering customers a broader range of instant, lab-grade insights across diverse applications. The synergy between NIRLAB's digital ecosystem and 908 Devices' existing expertise is anticipated to drive innovation in mobile analytical instrumentation.
The combination of NIRLAB's proven technology and global reach with 908 Devices' resources is poised to accelerate the development and deployment of next-generation mobile analytical solutions. The unified entity is expected to strengthen its position in the market for rapid, accurate, and accessible substance and material analysis, serving a wider array of industries and applications worldwide.